Breast Cancer News
In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
NEW YORK (Reuters Health) - Women with breast cancer who take common blood pressure drugs may have better odds of surviving the disease, according to two preliminary studies.
NEW YORK (Reuters Health) - More than eight out of 10 women say new guidelines recommending against routine breast cancer screening of women under 50 are "unsafe," according to a small survey.
Researchers found an association between obesity at diagnosis and overall survival in women with hormone-sensitive breast cancer, reports a study presented at the San Antonio Breast Cancer Symposium.
NEW YORK (Reuters Health) - Women newly diagnosed with earlier-stage breast cancer can take a few weeks to prepare for surgery without raising the odds that their tumor will progress, a new study suggests.
NEW YORK (Reuters Health) - Women taking breast cancer drugs are more likely to skip days or drop the treatment entirely if their co-pay is high, U.S. researchers have found.
FDA officials have invited the public to testify at a hearing that will argue the merits of bevacizumab (Avastin) as an approved treatment for HER2 negative metastatic breast cancer.
The National Comprehensive Cancer Network’s updated clinical practice guidelines for metastatic breast cancer retain bevacizumab as a treatment option and add two new therapies, the chemotherapy medicine eribulin and the RANKL inhibitor denosumab.
NEW YORK (Reuters Health) - Breast cancer screening that includes MRI scans might help find cancers at an earlier stage in high-risk women, reducing the likelihood that the tumors will become advanced before they're diagnosed, a new study suggests.
LONDON (Reuters) - Breast cancer patients who take the generic drug tamoxifen for five years are less likely to see their cancer return than those who take it for only two years, according to a large long-term study by British scientists.
FDA has agreed to Genentech’s request to revisit the agency’s decision to withdraw bevacizumab (Avastin) as an approved treatment for HER2 negative metastatic breast cancer. A public hearing is scheduled for June 28-29, and the resultant ruling is final.